<DOC>
	<DOCNO>NCT01576718</DOCNO>
	<brief_summary>This randomize , double-blind , placebo open-label active control , parallel-group , multicenter , dose range study male female subject age 12 year old severe persistent asthma remain symptomatic despite high dose inhale corticosteroid ( ICS ) therapy . The primary objective study evaluate dose response , efficacy safety 4 different dos fluticasone propionate ( Dose 1 , Dose 2 , Dose 3 , Dose 4 ) deliver Fluticasone Dry Powder Inhaler ( Fp DPI ) administer twice daily .</brief_summary>
	<brief_title>A Study Effectiveness Safety Different Doses Fluticasone Propionate Taken From Dry Powder Inhaler ( Puffer ) Adolescents Adults Who Have Asthma That Not Controlled High Dose Inhaled Corticosteroid Asthma Medications</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>1 . Written inform consent/assent sign date subject and/or parent /legal guardian conduct study related procedure . 2 . Male female 12 year old , Screening Visit . Male female 18 year old , Screening Visit , country local regulation regulatory status study medication permit enrollment adult . 3 . General good health , free concomitant condition treatment could interfere study conduct , influence interpretation study observations/results , put subject increase risk study . 4 . Asthma Diagnosis : Asthma define National Institutes Health ( NIH ) . 5 . Severity Disease : • A best forced expiratory volume one second ( FEV1 ) 40 % 85 % predict normal value Screening Visit . NHANES III predict value use subject age ≥12 year adjustments predict value make African American subject . ATS/ERS 2005 criterion acceptability , reproducibility , end test must meet spirometry 6 . Reversibility Disease : Demonstrated ≥12 % reversibility FEV1 within 30 minute follow 2 inhalation albuterol/salbutamol inhalation aerosol ( require , spacers permit reversibility test ) Screening Visit . If subject fails demonstrate increase FEV1 ≥12 % subject eligible study allow rescreen . Reversibility value 11.50 11.99 round 12 . Documented historical reversibility ≥ 12 % within 3 month Screening Visit accept . 7 . Current Asthma Therapy : Subjects require short act β2 agonist inhale corticosteroid minimum 8 week Screening Visit maintain stable dose inhale corticosteroid four week prior Screening Visit one follow dos : Fluticasone propionate HFA MDI ≥ 880 mcg/day Fluticasone propionate DPI≥ 1000 mcg/day Beclomethasone dipropionate DPI ≥ 2000 mcg/day Beclomethasone dipropionate HFA ( QVAR ) ≥ 640 mcg/day Beclomethasone dipropionate HFA ( Clenil Modulite ) ≥ 2000 mcg/day Budesonide DPI ≥ 1600 mcg/day Budesonide MDI ≥ 1600 mcg/day Flunisolide ≥ 2000 mcg/day Triamcinolone acetonide ≥ 2000 mcg /day Mometasone furoate DPI ≥ 880 mcg/day Ciclesonide HFA MDI ≥ 640 mcg/day Exception 1 : Based upon investigator 's judgment inherent harm change subject 's current ICS/LABA therapy subject provide consent , subject inhale Fluticasone propionate/salmeterol DPI ≥ 1000 mcg/day , Fluticasone propionate/salmeterol HFA ≥ 880 mcg/day , Fluticasone propionate/Formoterol ≥ 1000 mcg/day , Beclomethasone dipropionate/Formoterol ≥ 400 mcg/day , Budesonide/formoterol HFA ≥ 640 mcg/day , Budesonide/formoterol DPI ≥ 800 mcg/day , Mometasone furoate/formoterol MDI ≥ 800 mcg/day subject qualify ICS dose plus longacting β2agonists ( LABA ) administer via separate inhaler , may switch qualify dose fluticasone propionate provide subject participate PK portion study . Exception 2 : Subjects qualify dose fluticasone propionate wish participate PK portion study provide consent may fluticasone propionate switch different qualify ICS ( nonfluticasone propionate ) prescreening visit . The subject require return clinic complete Screening Visit follow 1week washout period . 8 . ShortActing β2Agonists : All subject must able replace current shortacting β2agonists albuterol/salbutamol inhalation aerosol Screening Visit use need duration study . The use spacer device meter dose inhaler ( MDI ) allow study exception 's use reversibility test Screening Visit . Nebulized albuterol/salbutamol allow time study . Subjects must able withhold inhale shortacting β2 sympathomimetic bronchodilator least 6 hour prior study visit . 9 . If female , currently pregnant , breast feeding , attempt become pregnant , negative serum pregnancy test , Nonchildbearing potential , define : Before menarche , 1 year postmenopausal , Surgically sterile ( tubal ligation , bilateral oophorectomy , hysterectomy ) , Congenital sterility , Diagnosed infertile undergoing treatment reverse infertility Childbearing potential , willing commit use consistent acceptable method birth control define duration study : Systemic contraception use 1 month prior screen , include birth control pill , transdermal patch ( Ortho Evra® ) , vaginal ring ( NuvaRing® ) , levonorgesterel ( Norplant® ) , injectable progesterone ( DepoProvera® ) , Double barrier method ( condom , cervical cap , diaphragm , vaginal contraceptive film spermicide ) , Intrauterine device ( IUD ) Monogamous vasectomize male partner Childbearing potential sexually active , willing commit use consistent acceptable method birth control define duration study , event subject become sexually active 10 . Capable understanding requirement , risk , benefit study participation , , judge investigator , capable give informed consent/assent compliant study requirement ( visit , recordkeeping , etc ) . 1 . History lifethreatening asthma define protocol asthma episode require intubation and/or associate hypercapnea , respiratory arrest hypoxic seizure . 2 . Culturedocumented suspected bacterial viral infection upper low respiratory tract , sinus , middle ear resolve within 2 week Screening Visit . In addition , subject must exclude infection occur Screening Visit Randomization Visit . 3 . Any asthma exacerbation require oral corticosteroid within 1 month Screening Visit . A subject must hospitalization asthma within 2 month prior Screening Visit . Note : An exacerbation asthma define worsen asthma require treatment rescue albuterol/salbutamol HFA MDI and/or subject 's regular inhale corticosteroid maintenance treatment . This include require use systemic corticosteroid and/or emergency room visit hospitalization , change subject 's regular inhale corticosteroid maintenance treatment , addition asthma medication . 4 . Presence glaucoma , cataract , ocular herpes simplex , malignancy basal cell carcinoma . 5 . Historical current evidence clinically significant disease include , limited : cardiovascular ( e.g. , congestive heart failure , know aortic aneurysm , clinically significant cardiac arrhythmia coronary heart disease ) , hepatic , renal , hematological , neuropsychological , endocrine ( e.g. , uncontrolled diabetes mellitus , uncontrolled thyroid disorder , Addison 's disease , Cushing 's syndrome ) , gastrointestinal ( e.g. , poorlycontrolled peptic ulcer , GERD ) , pulmonary ( e.g. , chronic bronchitis , emphysema , bronchiectasis need treatment , cystic fibrosis , bronchopulmonary dysplasia , chronic obstructive pulmonary disease ) . Significant defined disease , opinion investigator , would put safety subject risk participation , could affect efficacy safety analysis disease/condition exacerbate study . 6 . Have follow condition , judgment investigator , might cause participation study detrimental subject , include , limited : Current malignancy exclude basal cell carcinoma ; History malignancy acceptable subject remission one year prior Screening Visit . ( Remission define current evidence malignancy treatment malignancy 12 month prior Screening Visit ) Current untreated tuberculosis ; History tuberculosis acceptable subject receive approved prophylactic treatment regimen approve active treatment regimen evidence active disease minimum 2 year Uncontrolled hypertension ( systolic BP ≥160 diastolic BP &gt; 100 ) Stroke within 3 month prior Screening Visit Immunologic compromise 7 . History positive test HIV , hepatitis B hepatitis C infection . 8 . Untreated oral candidiasis Screening Visit . Subjects clinical visual evidence oral candidiasis agree receive treatment comply appropriate medical monitoring may enter study 9 . History adverse reaction intranasal , inhaled systemic corticosteroid therapy . Known suspected sensitivity constituent dry powder inhaler ( Spiromax Diskus ) use study ( i.e. , lactose ) . 10 . History severe allergy milk protein . 11 . Use systemic , oral depot corticosteroid within 4 week prior Screening Visit Use topical corticosteroid ( ≤1 % hydrocortisone cream ) dermatological disease permit Use intranasal corticosteroid ocular corticosteroid stable dose least 4 week prior Screening Visit throughout study permit 12 . Use immunosuppressive medication within 4 week prior Screening Visit study . 13 . Immunotherapy treatment allergy stable maintenance dose least 90 day prior Screening Visit remain stable dose without escalation throughout study permit . 14 . Use Cytochrome P450 3A4 ( CYP3A4 ) inhibitor ( e.g. , ritonavir , ketoconazole , itraconazole ) within 4 week prior Screening Visit . Strong moderate CYP3A4 inhibitor prohibit weak CYP3A4 allow . 15 . History alcohol drug abuse within two year precede Screening Visit . 16 . Current smoker smoke history 10 pack year ( pack year define smoke 1 pack cigarettes/day 1 year ) . A subject may use tobacco product within past one year ( e.g. , cigarette , cigar , chew tobacco , pipe tobacco ) . 17 . Study participation clinical investigator site employee and/or immediate relative . 18 . Study participation one subject household time . However , study completion discontinuation one subject another subject household may screen . 19 . Participation investigational drug study within 30 day ( start final followup visit ) precede Screening Visit plan participation another investigational drug study time study . 20 . Pregnancy , nursing , plan become pregnant donate gamete ( ova sperm ) vitro fertilization study period 30 day follow subject 's last study relate visit ( eligible subject applicable ) . Eligible female subject unwilling employ appropriate contraceptive measure ensure pregnancy occur study exclude .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Dose range</keyword>
	<keyword>Fluticasone Propionate</keyword>
	<keyword>Dry Powder Inhaler ( DPI )</keyword>
	<keyword>High Dose ICS</keyword>
	<keyword>Asthma</keyword>
</DOC>